Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 20/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.70 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.70 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.70 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.70 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21859675 | 1.00 | MAP4K1 (1.00) | MAP4K1MAP4K4KCNH2MAP4K2LRRK2 | |
| SCHEMBL30264757 | 1.00 | MAP4K1 (1.00) | MAP4K1MAP4K4KCNH2MAP4K2LRRK2 | |
| SCHEMBL30265569 | 1.00 | MAP4K1 (1.00) | MAP4K1MAP4K4KCNH2MAP4K2LRRK2 | |
| SCHEMBL21860005 | 0.86 | MAP4K1 (0.91) | MAP4K1 | |
| SCHEMBL30265059 | 0.86 | MAP4K1 (0.91) | MAP4K1 | |
| SCHEMBL20517184 | 0.86 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL20517471 | 0.83 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL20517473 | 0.83 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL20517470 | 0.83 | MAP4K1 (1.00) | MAP4K1 | |
| SCHEMBL30210279 | 0.83 | MAP4K1 (1.00) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020072695-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200108075-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108075-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | PHKG1, MAP4K5, HIPK1 | MAP4K1 9/4885MAP4K4 49/4885KCNH2 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.